SGLT2 Inhibitors and Perioperative Period

Launched by ASSIUT UNIVERSITY · Mar 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of a type of medication called SGLT2 inhibitors during the time around heart surgery, known as the perioperative period. Researchers at Assiut University want to see if these medications can help patients who have heart conditions, like coronary artery disease or valvular heart disease, have a better experience and fewer complications during and after surgery.

To participate in the trial, you need to be an adult with one of the heart conditions mentioned. However, if you have certain other health issues, like congenital heart disease, severe kidney problems, or are significantly overweight, you wouldn't be eligible to join. This trial is currently not recruiting participants yet, but once it starts, those who qualify will receive the SGLT2 inhibitors around the time of their surgery, and researchers will closely monitor their health outcomes. This could potentially lead to new insights on how to improve care for heart surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All subjects with coronary artery disease or valvular heart disease referred to cardiac surgery
• Exclusion Criteria:
• • 1. Congenital heart disease.
• • 2. Cardiomyopathy (EF\>40%).
• • 3. Sever renal impairment (eGFR\>30).
• • 4. COPD.
• • 5. Marked obesity (BMI\<35).
• • 6. Previous cardiac surgery.